Pfenex to Announce Second Quarter Financial Results on August 6
July 20 2020 - 8:30AM
Pfenex Inc. (NYSE American: PFNX) announced today that it will
report its financial results for the second quarter ended June 30,
2020, after the market close on Thursday, August 6, 2020. Pfenex
will host a conference call and webcast to discuss its financial
results and provide a company update that day at 1:30 PM Pacific
Time (4:30 PM Eastern Time).
Conference Call & Webcast
Thursday, August 6th @ 1:30 PM Pacific Time (4:30 PM
Eastern Time)
Domestic: 877-705-6003
(Domestic)
International: 201-493-6725
Conference ID: 13705182
The call will also be webcast and can be accessed from the
Investors section of the Company’s website at
www.pfenex.com or
http://public.viavid.com/index.php?id=140248.
A replay of the call will also be available through August 13th.
Participants may access the replay from the Investors section of
the Company’s website at www.pfenex.com or
http://public.viavid.com/index.php?id=140248.
About Pfenex Inc.
Pfenex is a development and licensing
biotechnology company with commercial products focused on
leveraging its proprietary protein production platform, Pfenex
Expression Technology®, to develop next generation and novel
protein therapeutics to meaningfully improve existing therapies and
create novel therapies for some of the biological targets linked to
critical diseases still waiting to successfully be addressed. Using
the patented Pfenex Expression Technology platform, Pfenex has
created a broad pipeline that is diversified across multiple
assets, including U.S. Food and Drug Administration (FDA) approved,
next generation and novel biopharmaceutical products. Pfenex’s lead
product is Teriparatide Injection (previously referred to as PF708
and Bonsity™), a therapeutic equivalent candidate to Forteo®
(teriparatide injection). Teriparatide Injection has been
commercialized in the U.S. for, among other uses, the treatment of
osteoporosis in certain patients at high risk for fracture, and
marketing authorization applications are pending in other
jurisdictions. In addition, Pfenex is developing hematologic
oncology products in collaboration with Jazz Pharmaceuticals,
including PF743, a recombinant Erwinia asparaginase, and PF745, a
half-life extended recombinant Erwinia asparaginase. Pfenex also
uses its Pfenex Expression Technology platform to produce CRM197, a
diphtheria toxoid carrier protein for use in prophylactic and
therapeutic vaccines.
Pfenex investors and others should note that
Pfenex announces material information to the public about Pfenex
through a variety of means, including its website
(http://www.pfenex.com/), its investor relations website
(http://pfenex.investorroom.com/), press releases, SEC filings,
public conference calls, corporate Twitter account
(https://twitter.com/pfenex), Facebook page
(https://www.facebook.com/Pfenex-Inc-105908276167776/timeline/),
and LinkedIn page (https://www.linkedin.com/company/pfenex-inc) in
order to achieve broad, non-exclusionary distribution of
information to the public and to comply with its disclosure
obligations under Regulation FD. Pfenex encourages its investors
and others to monitor and review the information Pfenex makes
public in these locations as such information could be deemed to be
material information. Please note that this list may be updated
from time to time.
Company Contact:
InvestorRelations@pfenex.com
Pfenex (AMEX:PFNX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Pfenex (AMEX:PFNX)
Historical Stock Chart
From Sep 2023 to Sep 2024